NICE recommends GSK’s ZEJULA (niraparib) for ovarian cancer patients
pharmafile | February 24, 2022 | News story | Business Services |
NICE has issued a Final Appraisal Determination (FAD), recommending the use of ZEJULA (niraparib) on the NHS. Niraparib is recommended for use a an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
This treatment is recommended only if they have a germline BRCA mutation and have had two courses of platinum-based chemotherapy or they do not have a germline BRCA mutation, and have had two or more courses of platinum-based chemotherapy, or if they do not have a germline BRCA mutations and have had two or more courses of platinum-based chemotherapy.
This guidance marks the first time that NICE has recommended a PARP inhibitor to be made available outside the CDF for patients with ovarian cancer, whether or not they carry a BRCA gene mutation.
Jack Harris, Vice President of Oncology, UK and Ireland at GSK, shared: “Recurrent advanced ovarian cancer remains challenging to treat and having access to options that may help slow the progression of this disease is key to maximising outcomes for those affected. The decision by NICE to recommend niraparib in this broad setting is therefore really important, and will now provide clarity for healthcare professionals and certainty of access. This is the outcome that everyone wanted and we are pleased that working in partnership with NICE, NHS England & Innovation, and the ovarian cancer community, has resulted in this welcome news.”
Victoria Clare, CEO at Ovacome, added: “For people living with the reality of advanced ovarian cancer, having access to a choice of treatments that may enable them live their day-to-day life more fully can be transformational. Today’s decision from NICE will not only provide reassurance for those needing treatment now, but also to others who could benefit from a choice of second-line maintenance therapies in the future.”
Lina Adams
